Here are three things to know.
1. Bivalirudin in 0.9 percent sodium chloride injection is an anticoagulant intended for patients undergoing percutaneous coronary intervention.
2. The medication “is the first and only available in a convenient frozen premixed solution,” said Robert Felicelli, president of pharmaceuticals for Baxter.
3. Baxter plans to launch Bivalirudin in two different dosages in early 2018.
More articles on supply chain:
Celgene to acquire Juno Therapeutics for $9B, betting on a future for CAR-T therapies
7 drug, devicemakers in the headlines
New Jersey imposes strict limits on pharma payments, gifts to clinicians
